Abstract P2-08-12: Interim analysis of the PREDICT Registry: Changes in treatment recommendation for a biologic signature predictive of radiation therapy (RT) benefit in patients with DCIS
Authors: Steven C Shivers, Pat W Whitworth, Rakesh Patel, Troy Bremer, Charles E Cox
Journal: Cancer Research (2022)

Abstract Background: The role of adjuvant RT following breast conserving surgery (BCS) for women with ductal carcinoma in situ (DCIS) remains controversial. Although there is level I evidence supporting the role of RT in reducing the risk of local recurrence, prognostic and predictive tools are needed to better stratify individual risks and benefits of RT. The DCISionRT® Test (PreludeDx, Laguna Hills, CA) is a biosignature that uses individual tumor biology in conjunction with clinical and pathologic risk factors. The test provides a validated score (DS) for women receiving BCS that assesses 10-year risk of DCIS recurrence and development of invasive breast cancer with and without adjuvant RT. We established a registry to evaluate the decision impact of DCISionRT on DCIS treatment recommendations. Methods: The PREDICT study is a prospective, multi-institutional registry for patients who received DCISionRT testing as part of their routine care. The registry includes females 26 and older who are diagnosed with DCIS and are candidates for BCS and eligible for RT or systemic therapy. Treating physicians completed treatment recommendation forms before and after receiving test reports to capture surgical, radiation and hormonal treatment (HT) recommendations and patient preferences. The primary endpoint is to identify the proportion of patients where testing led to a change in RT recommendation. Additional analyses include changes in recommendations in patient subgroups based on clinicopathologic factors or type of treating physician. Results: Analysis was performed in 969 patients treated at 55 sites who had definitive BCS and subsequent DCISionRT testing. The median age of patients was 62 years, 19% were 50 or younger, nuclear grade was high in 31% and tumor size was 2.5 cm or greater for 11%. Test results were DS Low risk (DS ≤ 3) for 63% of women and 37% were DS Elevated risk (DS &amp;gt; 3). Overall, RT recommendation (yes/no) was changed for 40% of women after DCISionRT testing and HT recommendation was changed for 11%. There was a net decrease in RT recommendation from 69% pre-assay to 50% post-assay (p&amp;lt;0.001). RT recommendation decreased by 42% in DS Low risk patients, but increased 22% in DS Elevated risk patients. Among physicians, surgeons were more likely to change their RT recommendation (49%) than radiation oncologists (38%). When test results indicated DS Elevated risk, both surgeons (82%) and radiation oncologists (91%) were likely to recommended RT, but when the results were low risk, surgeons were more likely than radiation oncologists to recommend omitting RT (83% vs. 68%, respectively). Conclusions: This interim analysis demonstrates a significant percent change in recommendations to add or omit RT based on DCISionRT results in 969 patients. Compared to traditional clinicopathologic features, the factor most strongly associated with RT recommendation was the DCISionRT result with other factors of importance being patient preference, tumor size and grade. The integration of DCISionRT into clinical decision processes has substantial impact on recommendations aimed at optimal management to prevent over- or under-treatment. TABLE 1. Impact of DCISionRT on adjuvant radiation recommended by clinicopathologic features.RT recommendedPre- to post-test change in RT recommendedTotal change in RT recommendedClinical factorNPre-test(%)Post-test(%)Net change (%)Yes to no (%)No to yes (%)Overall change (%)95% CIp-ValueAge, years&amp;lt; 501648148-3243133730-45%&amp;lt;0.001≥ 508056651-1642374137-44%&amp;lt;0.001Grade1 or 26656144-1650354440-47%&amp;lt;0.00133048764-2332333227-37%&amp;lt;0.001Tumor size≤ 2.5 cm8596648-1845354238-45%&amp;lt;0.001&amp;gt; 2.5 cm1109269-2327222619-35%&amp;lt;0.001RTOG 9804 criteria‘Good risk’5005541-1452344440-49%&amp;lt;0.001Not ‘good risk’4598460-2436353632-40%&amp;lt;0.001 Citation Format: Steven C Shivers, Pat W Whitworth, Rakesh Patel, Troy Bremer, Charles E Cox. Interim analysis of the PREDICT Registry: Changes in treatment recommendation for a biologic signature predictive of radiation therapy (RT) benefit in patients with DCIS [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-08-12.